Minn. R. agency 144, ch. 4717, HEALTH RISK LIMITS, pt. 4717.7860
This table lists the health risk limits derived from methods specified in parts 4717.7830, 4717.7840, and 4717.7850. For each chemical, this table specifies:
CAS number: 83-32-9
Year Adopted: 2018
Volatility: Moderate
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 200 | 100 | NA |
RfD (mg/kg-day) | -- | -- | 0.070 | 0.021 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.070 | 0.044 | -- |
Endpoints | -- | -- | adrenal, hepatic (liver) system | adrenal, hepatic (liver) system | -- |
CAS number: 103-90-2
Year Adopted: 2015
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 200 | 200 | 200 (2) | 200 (2) | NA |
RfD (mg/kg-day) | 0.25 | 0.25 | (2) | (2) | -- |
RSC | 0.2 | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | -- |
Endpoints | hepatic (liver) system | hepatic (liver) system | hepatic (liver) system | hepatic (liver) system | -- |
CAS number: 34256-82-1
Year Adopted: 2018
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 30 | 30 | 20 | NA |
RfD (mg/kg-day) | -- | 0.016 | 0.012 | 0.0039 | -- |
RSC | -- | 0.5 | 0.2 | 0.2 | -- |
SF (per mg/ kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | 0.070 | 0.044 | -- |
Endpoints | -- | developmental, hepatic (liver) system, thyroid (E) | hepatic (liver) system, male reproductive system, nervous system, renal (kidney) system | hepatic (liver) system, male reproductive system, nervous system, renal (kidney) system, respiratory system | -- |
CAS number: 187022-11-3
Year Adopted: 2018
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 500 | 500 | 300 | NA |
RfD (mg/kg-day) | -- | 0.29 | 0.19 | 0.056 | -- |
RSC | -- | 0.5 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/ kg-day) | -- | 0.285 | 0.070 | 0.044 | -- |
Endpoints | -- | thyroid (E) | male reproductive system, thyroid (E) | male reproductive system, thyroid (E) | -- |
CAS number: 184992-44-4
Year Adopted: 2018
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 100 | 100 (2) | 90 | NA |
RfD (mg/kg-day) | -- | 0.081 | (2) | 0.019 | -- |
RSC | -- | 0.5 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | (2) | 0.044 | -- |
Endpoints | -- | thyroid (E) | thyroid (E) | thyroid (E) | -- |
CAS number: 67-64-1
Year Adopted: 2023
Volatility: Moderate
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 5,000 | 5,000 (2) | 3,000 | NA |
RfD (mg/kg-day) | -- | 3.1 | (2) | 0.69 | -- |
RSC | -- | 0.5 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | 0.045 | -- |
Endpoints | -- | renal (kidney) system | renal (kidney) system | hematological (blood) system, hepatic (liver) system, renal (kidney) system | -- |
CAS number: 21145-77-7 or 1506-02-1
Year Adopted: 2013
Volatility: Moderate
| Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL ( µg/L) | ND | 100 | 30 | 20 | NA |
RfD (mg/kg-day) | -- | 0.070 | 0.011 | 0.0037 | -- |
RSC | -- | 0.5 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | 0.077 | 0.043 | -- |
Endpoints | -- | hepatic (liver) system | hepatic (liver) system | hepatic (liver) system | -- |
CAS number: 79-06-1
Year Adopted: 2015
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL µg/L) | ND | 7 | 7 (2) | 7 (2) | 0.2 |
RfD (mg/kg-day) | -- | 0.010 | (2) | (2) | -- |
RSC | -- | 02 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 05 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3(ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | -- | 0.289 | (2) | (2) | 0.137(<2) 0.047 (2 to <16) 0.039(16+) |
Endpoints | -- | developmental, male reproductive system, nervous system | developmental, male reproductive system, nervous system | developmental, male repro ductive system, nervous system | cancer |
CAS number: 15972-60-8
Year Adopted: 2018
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 100 | 60 | 9 | NA |
RfD (mg/kg-day) | -- | 0.077 | 0.020 | 0.0020 | -- |
RSC | -- | 0.5 | 0.2 | 0.2 | -- |
SF (per mg/ kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | 0.070 | 0.044 | -- |
Endpoints | -- | developmental, renal (kidney) system | hematological (blood) system, hepatic (liver) system, renal (kidney) system | hematological (blood) system, hepatic (liver) system, renal (kidney) system | -- |
CAS number: 1066-51-9
Year Adopted: 2023
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 3,000 | 1,000 | -- |
RfD (mg/kg-day) | -- | -- | 0.96 | 0.32 | -- |
RSC | -- | -- | 02 | 02 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF orlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.074 | 0.045 | -- |
Endpoints | -- | -- | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | -- |
CAS number: 1912-24-9
Year Adopted: 2009
Volatility: Nonvolatile
MCL-based HRL: 3 µg/L
CAS number: 25057-89-0
Year Adopted: 2015
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 400 | 60 | 50 | 30 | NA |
RfD (mg/kg-day) | 0.22 | 0.033 | 0.020 | 0.0060 | -- |
RSC | 0.5 | 0.5 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | 0.077 | 0.043 | -- |
Endpoints | developmental, female reproductive system | developmental | hematological fblood) system | thyroid | -- |
CAS number: 71-43-2
Year Adopted: 2009
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL ( µg/L) | 10 | 10 | 3 | 3 (3) | 2 |
RfD (mg/kg-day) | 0.015 | 0.014 | 0.0013 | (3) | -- |
RSC | 0.2 | 0.2 | 0.2 | (3) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.055 |
ADAF | -- | -- | -- | -- | 10 (ADAF<2) |
3 (ADAF2 to <16) | |||||
1 (ADAF16+) | |||||
Intake Rate | 0.289 | 0.289 | 0.077 | (3) | 0.137 (<2) |
(L/kg-day) | 0.047 (2 to <16) | ||||
0.039 (16+) | |||||
Endpoints | develop- mental | hemato- logical (blood) system, immune system | hemato- logical (blood) system, immune system | hemato- logical (blood) system, immune system | cancer |
CAS number: 50-32-8
Year Adopted: 2023
Volatility: Low
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 05 | 0.5 (2) | 0.5 (2) | 0.1 |
RfD (mg/kg-day) | -- | 0.00031 | (2) | (2) | -- |
RSC | -- | 05 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 1 |
ADAF or lifetime | 10 (ADAF<2) 3 (ADAF 2 to <16 1 (ADAF 16+) | ||||
Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | 0.155 (<2) |
0.040 (2 to <16) | |||||
0.042 (16+) | |||||
Endpoints | -- | developmental, nervous system | developmental, nervous system | developmental, nervous system | cancer |
CAS number: 119-61-9
Year Adopted: 2023
Volatility: Low
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 900 | 100 | 100 (3) | NA |
RfD (mg/kg-day) | -- | 0.52 | 0.053 | (3) | -- |
RSC | -- | 0.5 | 0.2 | (3) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | 0.074 | (3) | -- |
Endpoints | -- | developmental | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | -- |
CAS number: 95-14-7
Year Adopted: 2023
Volatility: Low
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 20 | 20 (2) | 20 (2) | NA |
RfD (mg/kg-day) | -- | 0.023 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
Endpoints | -- | developmental | developmental | developmental | -- |
CAS number: 92-52-4
Year Adopted: 2023
Volatility: Moderate
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 400 | 100 | 100 (2) | 100 (2) | 10 |
RfD (mg/kg-day) | 0.58 | 0.18 | (2) | (2) | -- |
RSC | 0.2 | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.008 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | 0.290 | 0.290 | (2) | (2) | 0.155 (<2) 0.040 (2 to <16) |
0.042 n.+. | |||||
Endpoints | renal (kidney) system | renal (kidney) system | renal (kidney) system | renal (kidney) system | cancer |
CAS number: 80-05-7
Year Adopted: 2015
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 100 | 20 | 20(3) | NA |
RfD (mg/kg-day) | -- | 0.16 | 0.0065 | (3) | -- |
RSC | -- | 0.2 | 0.2 | (3) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | 0.077 | (3) | -- |
Endpoints | developmental, female reproductive system (E), hepatic (liver) system, male reproductive system (E), renal (kidney) system, thyroid (E) | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system |
CAS number: 75-27-4
Year Adopted: 2023
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 400 | 30 | 30 (2) | 30 | 3 |
RfD (mg/kg-day) | 0.073 | 0.039 | (2) | 0.0075 | -- |
RSC | 0.2 | 0.2 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.035 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | 0.038 | 0.290 | (2) | 0.045 | 0.155 (<2) 0.040 (2 to <16) 0.042 (16+) |
Endpoints | female reproductive system (E) | immune system, spleen | immune system, spleen | hepatic (liver) system | cancer |
CAS number: 85-68-7
Year Adopted: 2015
Volatility: Low
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 100 | 100 | 100 (2) | 100 (2) | NA |
RfD (mg/kg-day) | 0.15 | 0.15 | (2) | (2) | -- |
RSC | 0.2 | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | -- |
Endpoints | developmental (E) | developmental (E) | developmental (E) | developmental (E) | -- |
CAS number: 7440-43-9
Year Adopted: 2015
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 5 | 1 | 1 | 0.5 | NA |
RfD (mg/kg-day) | 0.0077 | 0.0016 | 0.00044 | 0.00011 | -- |
RSC | 0.2 | 0.2 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | 0.077 | 0.043 | -- |
Endpoints | developmental | developmental, nervous system, renal (kidney) system | developmental, skeletal | renal (kidney) system, skeletal | -- |
CAS number: 298-46-4
Year Adopted: 2013
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 40 | 40 | 40 (2) | 40 (2) | NA |
RfD (mg/kg-day) | 0.013 | 0.013 | (2) | (2) | -- |
RSC | 0.8 | 0.8 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | -- |
Endpoints | developmental, nervous system | developmental, hematological (blood) system, hepatic (liver) system, immune system, nervous system, male reproductive system (E), female reproductive system (E), thyroid (E) | developmental, hematological (blood) system, hepatic (liver) system, immune system, nervous system, male reproductive system (E), female reproductive system (E), thyroid (E) | developmental, hematological (blood) system, hepatic (liver) system, immune system, nervous system, male reproductive system (E), female reproductive system (E), thyroid (E) | -- |
CAS number: 56-23-5
Year Adopted: 2013
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 100 | 3 | 3 (2) | 3 (2) | 1 |
RfD (mg/kg-day) | 0.18 | 0.0037 | (2) | (2) | -- |
RSC | 0.2 | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.07 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | 0.137 (<2) 0.047 (2 to <16) 0.039 (16+) |
Endpoints | developmental, hepatic (liver) system | hepatic (liver) system | hepatic (liver) system | hepatic (liver) system | cancer |
CAS number: 67-66-3
Year Adopted: 2018
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 20 | 20 (2) | 20 (2) | NA |
RfD (mg/kg-day) | -- | 0.022 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/ kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
Endpoints | -- | developmental, hepatic (liver) system, immune system | developmental, hepatic (liver) system, immune system | developmental, hepatic (liver) system, immune system | -- |
CAS number: 210880-92-5, 205510-53-8
Year Adopted: 2018
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 200 | 200 (2) | 200 (2) | NA |
RfD (mg/kg-day) | -- | 0.093 | (2) | (2) | -- |
RSC | -- | 0.5 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
Endpoints | -- | developmental | developmental | developmental | -- |
CAS number: 21725-46-2
Year Adopted: 2018
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 3 | 3 | 3 | 1 | NA |
RfD (mg/ kg-day) | 0.0015 | 0.0015 | 0.0012 | 0.00022 | -- |
RSC | 0.5 | 0.5 | 0.2 | 0.2 | -- |
SF (per mg/ kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.285 | 0.285 | 0.070 | 0.044 | -- |
Endpoints | developmental, female reproductive system | developmental, female reproductive system | developmental, female reproductive system, hepatic (liver) system, renal (kidney) system | None | -- |
CAS number: 84-74-2
Year Adopted: 2015
Volatility: Low
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 20 | 20 | 20 (2) | 20 (2) | NA |
RfD (mg/kg-day) | 0.023 | 0.023 | (2) | (2) | -- |
RSC | 0.2 | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | -- |
Endpoints | developmental (E) | developmental (E) | developmental (E) | developmental (E) | -- |
CAS number: 106-46-7
Year Adopted: 2023
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 50 | 50(2) | 50(2) | NA |
RfD (mg/kg-day) | -- | 0.069 | (2) | (2) | -- |
RSC | -- | 02 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or lifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
Endpoints | -- | developmental, hepatic (liver) system, nervous system | developmental, hepatic (liver) system, nervous system | developmental, hepatic (liver) system, nervous system | -- |
CAS number: 75-71-8
Year Adopted: 2011
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | ND | 700 | NA |
RfD (mg/kg-day) | -- | -- | -- | 0.15 | -- |
RSC | -- | -- | -- | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF orlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | -- | 0.043 | -- |
Endpoints | -- | -- | -- | None | -- |
CAS number: 107-06-2
Year Adopted: 2013
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 200 | 200 (2) | 60 | 1 |
RfD (mg/kg-day) | -- | 0.23 | (2) | 0.012 | -- |
RSC | -- | 0.2 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.091 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | -- | 0.289 | (2) | 0.043 | 0.137 (<2) 0.047 (2 to <16) 0.039 (16+) |
Endpoints | -- | hepatic (liver) system | hepatic (liver) system | renal (kidney) system, hepatic (liver) system | cancer |
CAS number: 156-60-5
Year Adopted: 2023
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 50 | 9 | NA |
RfD (mg/kg-day) | -- | -- | 0.020 | 0.0020 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.074 | 0.045 | -- |
Endpoints | -- | -- | immune system | immune system | -- |
CAS number: 75-35-4
Year Adopted: 2023
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 200 | 200 | NA |
RfD (mg/kg-day) | -- | -- | 0.069 | 0.040 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.074 | 0.045 | -- |
Endpoints | -- | -- | hepatic (liver) system | hepatic (liver) system | -- |
CAS number: 78-87-5
Year Adopted: 2023
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 20 | 20 (2) | 20 (2) | 3 |
RfD (mg/kg-day) | -- | 0.029 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.037 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | 0.155(<2) 0.040(2 to<16) 0.042 (16+) |
Endpoints | -- | developmental | developmental | developmental | cancer |
CAS number: 156-59-2
Year Adopted: 2018
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 20 | 10 | 6 | NA |
RfD (mg/kg-day) | -- | 0.033 | 0.0043 | 0.0013 | -- |
RSC | -- | 0.2 | 0.2 | 0.2 | -- |
SF (per mg/ kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | 0.070 | 0.044 | -- |
Endpoints | -- | hepatic (liver) system | renal (kidney) system | renal (kidney) system | -- |
CAS number: 75-09-2
Year Adopted: 2009
Volatility: High
MCL-based HRL: 5 µg/L
CAS number: 94-75-7
Year Adopted: 2018
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 30 | 30 (2) | 30 (2) | NA |
RfD (mg/kg-day) | -- | 0.048 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/ kg-day) | -- | 0.285 | (2) | (2) | -- |
Endpoints | -- | adrenal, developmental, thyroid (E) | adrenal, developmental, thyroid (E) | adrenal, developmental, thyroid (E) | -- |
CAS number: 60-57-1
Year Adopted: 2018
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 0.2 | 0.2 (2) | 0.2 | 0.006 |
RfD (mg/ kg-day) | -- | 0.00011 | (2) | 0.000043 | -- |
RSC | -- | 0.5 | (2) | 0.2 | -- |
SF (per mg/ kg-day) | -- | -- | -- | -- | 16 |
AFlifetime | -- | -- | -- | -- | 2.5 |
Intake Rate (L/kg-day) | -- | 0.285 | (2) | 0.044 | 0.044 |
Endpoints | -- | developmental, immune system, nervous system | developmental, immune system, nervous system | developmental, hepatic (liver) system, immune system, nervous system | cancer |
CAS number: 117-81-7
Year Adopted: 2015
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 20 | 20 | 20 (2) | 20 (2) | 7 |
RfD (mg/kg-day) | 0.029 | 0.029 | (2) | (2) | -- |
RSC | 0.2 | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.014 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | 0.137(<2) 0.047(2 to <16) 0.039(16+) |
Endpoints | developmental (E), male reproductive system (E) | developmental (E),male reproductive system (E) | developmental (E), male reproductive system (E) | developmental (E), male repro ductive system (E) | cancer |
CAS number: 134-62-3
Year Adopted: 2013
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL ( µg/L) | ND | 200 | 200 (2) | 200 (2) | NA |
RfD (mg/kg-day) | -- | 0.23 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | (2) | (2) | -- |
Endpoints | -- | developmental, nervous system | developmental, nervous system | developmental, nervous system | -- |
CAS numbers: 87674-68-8 and 163515-14-8
Year Adopted: 2015
Volatility: Moderate
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 600 | 600 (2) | 300 | NA |
RfD (mg/kg-day) | -- | 0.34 | (2) | 0.060 | -- |
RSC | -- | 0.5 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | (2) | 0.043 | -- |
Endpoints | -- | developmental, female reproductive system, hepatic (liver) system, nervous system | developmental, female reproductive system, hepatic (liver) system, nervous system | hepatic (liver) system | -- |
CAS number: 88-85-7
Year Adopted: 2018
Volatility: Moderate
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 8 | 8 (2) | 8 (2) | NA |
RfD (mg/kg-day) | -- | 0.0048 | (2) | (2) | -- |
RSC | -- | 0.5 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
Endpoints | -- | developmental | developmental | developmental | -- |
CAS number: 123-91-1
Year Adopted: 2013
Volatility: Low
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 300 | 100 | 1 |
RfD (mg/kg-day) | -- | -- | 0.12 | 0.025 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/ kg-day) | -- | -- | -- | -- | 0.1 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate | -- | -- | 0.077 | 0.043 | 0.137 (<2) |
(L/kg-day) | 0.047(2 to <16) 0.039 (16+) | ||||
Endpoints | -- | -- | hepatic (liver) system, renal (kidney) system, respiratory system | hepatic (liver) system, renal (kidney) system, respiratory system | cancer |
CAS number: 57-63-6
Year Adopted: 2023
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 0.0005 | 0.0002 | 0.0002 | NA |
RfD (mg/kg-day) | -- | 1.7 x 10-7 | 1.4 x 10-8 | 1.4 x 10-8 | -- |
RSC | -- | 0.8 | 0.8 | 0.8 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | 0.074 | 0.045 | -- |
Endpoints | -- | developmental (E), female reproductive system (E), male reproductive system (E) | developmental | developmental | -- |
CAS number: 100-41-4
Year Adopted: 2023
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 40 | 40 (2) | 40 (2) | NA |
RfD (mg/kg-day) | -- | 0.06 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
Endpoints | -- | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | -- |
CAS number: 759-94-4
Year Adopted: 2018
Volatility: Moderate
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 300 | 300 | 90 | 40 | NA |
RfD (mg/kg-day) | 0.16 | 0.16 | 0.033 | 0.0083 | -- |
RSC | 0.5 | 0.5 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.285 | 0.285 | 0.070 | 0.044 | -- |
Endpoints | nervous system | developmental, female reproductive system, nervous system | cardiovascular system | cardiovascular system | -- |
CAS number: 107-21-1
Year Adopted: 2023
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 2,000 | 2,000 | 2,000 | NA |
RfD (mg/kg-day) | -- | 0.33 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.038 | (2) | (2) | -- |
Endpoints | -- | developmental | developmental, renal (kidney) system | developmental, male reproductive system, renal (kidney) system | -- |
CAS number: 206-44-0
Year Adopted: 2018
Volatility: Low
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 200 | 70 | NA |
RfD (mg/kg-day) | -- | -- | 0.053 | 0.016 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.070 | 0.044 | -- |
Endpoints | -- | -- | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | -- |
CAS number: 86-73-7
Year Adopted: 2023
Volatility: Moderate
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 200 | 80 | NA |
RfD (mg/kg-day) | -- | -- | 0.058 | 0.018 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.074 | 0.045 | -- |
Endpoints | -- | -- | hematological (blood) system, spleen | hematological (blood) system, spleen | -- |
CAS number: 72178-02-0
Year Adopted: 2023
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 200 | 200 (2) | 20 | NA |
RfD (mg/kg-day) | -- | 0.12 | (2) | 0.005 | -- |
RSC | -- | 0.5 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | 0.045 | -- |
Endpoints | -- | developmental, hepatic (liver) system, immune system | developmental, hepatic (liver) system, immune system | hepatic (liver) system | -- |
CAS number: 138261-41-3
Year Adopted: 2023
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 100 | 2 | 2 (2) | 2 (2) | NA |
RfD (mg/kg-day) | 0.15 | 0.0036 | (2) | (2) | -- |
RSC | 0.2 | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.290 | 0.290 | (2) | (2) | -- |
Endpoints | nervous system | immune system | immune system | immune system | -- |
CAS number: 7439-96-5
Year Adopted: 2023
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 100 | ND | ND | NA |
RfD (mg/kg-day) | -- | 0.083 | -- | -- | -- |
RSC | -- | 0.5 | -- | -- | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | -- | -- | -- |
Endpoints | -- | developmental, nervous system | -- | -- | -- |
CAS number: 51218-45-2; 87392-12-9
Year Adopted: 2023
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 300 | 300 (2) | 300 (2) | NA |
RfD (mg/kg-day) | -- | 0.19 | (2) | (2) | -- |
RSC | -- | 0.5 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
Endpoints | -- | developmental | developmental | developmental | -- |
CAS number: 171118-09-5 Year Adopted: 2023 Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 7,000 | 1,000 | NA |
RfD (mg/kg-day) | -- | -- | 2.7 | 0.27 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.074 | 0.045 | -- |
Endpoints | -- | -- | hepatic (liver) system | hepatic (liver) system | -- |
CAS number: 152019-73-3
Year Adopted: 2023
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 5,000 | 5,000 (2) | 1,000 | NA |
RfD (mg/kg-day) | -- | 2.7 | (2) | 0.27 | -- |
RSC | -- | 0.5 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | 0.045 | -- |
Endpoints | -- | none | none | none | -- |
CAS number: 21087-64-9
Year Adopted: 2013
Volatility: Low
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 30 | 10 | 10 (2) | 10 (2) | NA |
RfD (mg/kg-day) | 0.016 | 0.006 | (2) | (2) | -- |
RSC | 0.5 | 0.5 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | -- |
Endpoints | developmental, nervous system | thyroid (E) | thyroid (E) | thyroid (E) | -- |
CAS number: 91-20-3
Year Adopted: 2013
Volatility: Moderate
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 70 | 70 | 70 (2) | 70 | NA |
RfD (mg/kg-day) | 0.038 | 0.038 | (2) | 0.016 | -- |
RSC | 0.5 | 0.5 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | 0.043 | -- |
Endpoints | nervous system | nervous system | nervous system | nervous system, spleen | -- |
CAS number: 14797-55-8
Year Adopted: 2009
Volatility: Nonvolatile
MCL-based HRL: 10,000 µg/L
CAS number: 84852-15-3
Year Adopted: 2023
Volatility: Low
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 100 | 40 | 20 | NA |
RfD (mg/kg-day) | -- | 0.21 | 0.016 | 0.0049 | -- |
RSC | -- | 0.2 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | 0.074 | 0.045 | -- |
Endpoints | -- | developmental, female reproductive system | renal (kidney) system | renal (kidney) system | -- |
CAS number: 140-66-9
Year Adopted: 2023
Volatility: Low
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 100 | 100 (2) | 100 (2) | NA |
RfD (mg/kg-day) | -- | 0.17 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
Endpoints | -- | developmental | developmental | developmental | -- |
CAS number: 87-86-5
Year Adopted: 2015
Volatility: Low
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 7 | 7 | 7 (2) | 7 (2) | 0.3 |
RfD (mg/kg-day) | 0.0040 | 0.0040 | (2) | (2) | -- |
RSC | 0.5 | 0.5 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.4 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | 0.137(<2) 0.047(2 to <16) 0.039(16+) |
Endpoints | developmental, thyroid (E) | developmental (E), thyroid (E) | developmental (E), hepatic (liver) system, immune system, male reproductive system, thyroid (E) | developmental (E), hepatic (liver) system, immune system, male reproductive system, thyroid (E) | cancer |
CAS number: 45187-15-3; 375-73-5; 29420-49-3; 68259-10-9; 60453-92-1
Year Adopted: 2023
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 0.1 | 0.1 (2) | 0.1 (2) | NA |
RfD (mg/kg-day) | -- | 0.000084 | (2) | (2) | -- |
RSC | -- | 0.5 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
Endpoints | -- | thyroid (E) | thyroid (E) | thyroid (E) | -- |
CAS number: 45048-62-2; 375-22-4
Year Adopted: 2018
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 7 | 7 (2) | 7 (2) | NA |
RfD (mg/kg-day) | -- | 0.0038 | (2) | (2) | -- |
RSC | -- | 0.5 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/ kg-day) | -- | 0.285 | (2) | (2) | -- |
Endpoints | -- | hepatic (liver) system, thyroid (E) | hepatic (liver) system, thyroid (E) | hepatic (liver) system, thyroid (E) | -- |
CAS number: 108427-53-8; 355-46-4; 3871-99-6
Year Adopted: 2023
Volatility: Moderate
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | NA | 0.047 | 0.047 | 0.047 | NA |
RfD (mg/kg-day) | -- | 0.0000097 | 0.0000097 | 0.0000097 | -- |
RSC | -- | 0.5 | -- | -- | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | * | * | * | -- |
Endpoints | -- | hepatic (liver) system, thyroid (E) | hepatic (liver) system, thyroid (E) | hepatic (liver) system, thyroid (E) | -- |
* 95th percentile water intake rates (Tables 3-1, 3-3, and 3-5 Environmental Protection Agency, Exposure Factors Handbook, 2019) or upper percentile breast milk intake rates (Table 15-1, Environmental Protection Agency, Exposure Factors Handbook, 2011), and MDH background information.
CAS number: 92912-52-7; 307-24-4; 21615-47-4; 2923-26-4
Year Adopted: 2023
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 0.2 | 0.2 (2) | 0.2 (2) | NA |
RfD (mg/kg-day) | -- | 0.00032 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
Endpoints | -- | developmental, thyroid (E) | developmental, thyroid (E) | developmental, thyroid (E) | -- |
CAS number: 45298-90-6; 1763-23-1; 29081-56-9; 2795-39-3; 70225-14-8; and 29457-72-5
Year Adopted: 2009
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | ND | 0.3 | NA |
RfD (mg/kg-day) | -- | -- | -- | 0.00008 | -- |
RSC | -- | -- | -- | 0.2 | -- |
SF (per mg/ kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | -- | 0.049 | -- |
Endpoints | -- | -- | -- | developmental, hepatic (liver) system, thyroid (E) | -- |
CAS number: 45285-51-6; 335-67-1; 335-66-0; 3825-26-1; 2395-00-8; 335-93-3; and 335-95-5
Year Adopted: 2018
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 0.035 | 0.035 | 0.035 | NA |
RfD (mg/kg-day) | -- | 0.000018 | 0.000018 | 0.000018 | -- |
RSC | -- | 0.5 | 0.5 | 0.5 | -- |
SF (per mg/ kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | * | * | * | -- |
Endpoints | -- | developmental, hepatic (liver) system, immune system, renal (kidney) system | developmental, hepatic (liver) system, immune system, renal (kidney) system | developmental, hepatic (liver) system, immune system, renal (kidney) system | -- |
* 95th percentile water intake rates (Tables 3-1 and 3-3), or upper percentile breast milk intake rates (Table 15-1), Environmental Protection Agency (EPA) Exposure Factors Handbook, 2011.
CAS number: 129-00-0
Year Adopted: 2018
Volatility: Moderate
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 90 | 50 | NA |
RfD (mg/kg-day) | -- | -- | 0.033 | 0.010 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.070 | 0.044 | -- |
Endpoints | -- | -- | renal (kidney) system | renal (kidney) system | -- |
CAS number: 91-22-5
Year Adopted: 2023
Volatility: Low
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | ND | 4 | 0.03 |
RfD (mg/kg-day) | -- | -- | -- | 0.00079 | -- |
RSC | -- | -- | -- | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 3 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | -- | -- | -- | 0.045 | 0.155 (<2) 0.040 (2 to <16) 0.042 (16+) |
Endpoints | -- | -- | -- | hematological (blood) system, hepatic (liver) system, renal (kidney) system, respiratory system, and spleen | cancer |
CAS number: 122-34-9
Year Adopted: 2009
Volatility: Nonvolatile
MCL-based HRL: 4 µg/L
CAS number: 57-68-1 (1981-58-4)
Year Adopted: 2015
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 100 | 100 (2) | 100 (2) | NA |
RfD (mg/kg-day) | -- | 0.040 | (2) | (2) | -- |
RSC | -- | 0.8 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | (2) | (2) | -- |
Endpoints | -- | thyroid | thyroid | thyroid | -- |
CAS number: 127-18-4
Year Adopted: 2023
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 7 | 7 (3) | 4 |
RfD (mg/kg-day) | -- | -- | 0.0026 | (3) | -- |
RSC | -- | -- | 0.2 | (3) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.0249 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | -- | -- | 0.074 | (3) | 0.155 (<2) 0.040 (2 to <16) 0.042 (16+) |
Endpoints | -- | -- | nervous system | nervous system | cancer |
CAS number: 109-99-9
Year Adopted: 2018
Volatility: Moderate
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 600 | 600 (2) | 600 (2) | NA |
RfD (mg/kg-day) | -- | 0.82 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
Endpoints | -- | developmental | developmental | developmental | -- |
CAS number: 153719-23-4
Year Adopted: 2018
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 400 | 200 | 200 (3) | NA |
RfD (mg/kg-day) | -- | 0.25 | 0.057 | (3) | -- |
RSC | -- | 0.5 | 0.2 | (3) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/ kg-day) | -- | 0.285 | 0.070 | (3) | -- |
Endpoints | -- | developmental, female reproductive system, hepatic (liver) system | male reproductive system | male reproductive system | -- |
CAS number: 108-88-3
Year Adopted: 2023
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 70 | 70 (2) | 70 (2) | NA |
RfD (mg/kg-day) | -- | 0.10 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
Endpoints | -- | immune system, nervous system | immune system, nervous system | immune system, nervous system | -- |
CAS number: 120-82-1
Year Adopted: 2013
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 100 | 100 (2) | 100 | 4 |
RfD (mg/kg-day) | -- | 0.17 | (2) | 0.021 | -- |
RSC | -- | 0.2 | (2) | 0.2 | -- |
SF (per mg/ kg-day) | -- | -- | -- | -- | 0.029 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | -- | 0.289 | (2) | 0.043 | 0.137 (<2) 0.047 (2 to <16) 0.039 (16+) |
Endpoints | -- | hepatic (liver) system, adrenal (E), hemato-logical (blood) system | hepatic (liver) system, adrenal (E), hemato-logical (blood) system | hepatic (liver) system, adrenal (E), renal (kidney) system | cancer |
CAS number: 71-55-6
Year Adopted: 2018
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 9,000 | 5,000 | NA |
RfD (mg/kg-day) | -- | -- | 3.0 | 1.0 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/ kg-day) | -- | -- | 0.070 | 0.044 | -- |
Endpoints | -- | -- | hepatic (liver) system, male reproductive system | hepatic (liver) system, male reproductive system | -- |
CAS number: 79-01-6
Year Adopted: 2015
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 0.4 | 0.4 | 0.4 (3) | 2 |
RfD (mg/kg-day) | -- | 0.00052 | 0.00017 | (3) | -- |
RSC | -- | 0.2 | 0.2 | (3) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.05 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | -- | 0.289 | 0.077 | (3) | 0.137 (<2) 0.047 (2 to <16) 0.039 (16+) |
Endpoints | -- | develop-mental, immune system | develop-mental, immune system | develop-mental, immune system | cancer |
CAS number: 93-72-1
Year Adopted: 2009
Volatility: Nonvolatile
MCL-based HRL: 50 µg/L
CAS number: 96-18-4
Year Adopted: 2013
Volatility: Moderate
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL ( µg/L) | 7 | 7 | 7 (2) | 7 (2) | 0.003 |
RfD (mg/kg-day) | 0.0042 | 0.0042 | (2) | (2) | -- |
RSC | 0.5 | 0.5 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 30 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | 0.137 (<2) 0.047 (2 to <16) 0.039 (16+) |
Endpoints | develop-mental | develop-mental | develop-mental | develop-mental | cancer |
CAS number: 526-73-8
Year Adopted: 2023
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 30 | 30 (2) | 30 (2) | NA |
RfD (mg/kg-day) | -- | 0.042 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
Endpoints | -- | nervous system | nervous system | nervous system | -- |
CAS number: 95-63-6
Year Adopted: 2023
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 30 | 30(2) | 30(2) | NA |
RfD (mg/kg-day) | -- | 0.042 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2} | (2} | -- |
Endpoints | -- | nervous system | nervous system | nervous system | -- |
CAS number: 108-67-8
Year Adopted: 2009
2023 Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 30 | 30 (2) | 30 (2) | NA |
RfD (mg/kg-day) | -- | -- | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
Endpoints | -- | nervous system | nervous system | nervous system | -- |
CAS number: 13674-87-8
Year Adopted: 2023
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 20 | 8 | 0.8 |
RfD (mg/kg-day) | -- | -- | 0.0067 | 0.0019 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.13 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to<16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | -- | -- | 0.074 | 0.045 | 0.155(<2) 0.040(2 to<16) 0.042 (16+) |
Endpoints | -- | -- | hepatic (liver) system; kidney system | male reproductive system; renal (kidney) system | cancer |
CAS number: 78-51-3
Year Adopted: 2023
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 30 | 30 (2) | 30 | NA |
RfD (mg/kg-day) | -- | 0.043 | (2) | 0.0074 | -- |
RSC | -- | 0.2 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | 0.045 | -- |
Endpoints | -- | hepatic (liver) system | hepatic (liver) system | hepatic (liver) system | -- |
CAS number: 115-96-8
Year Adopted: 2013
Volatility: Low
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 300 | 200 | 200 (3) | 5 |
RfD (mg/kg-day) | -- | 0.15 | 0.068 | (3) | -- |
RSC | -- | 0.5 | 0.2 | (3) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.02 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1(ADAF16+) |
Intake Rate (L/kg-day) | -- | 0.289 | 0.077 | (3) | 0.137 (<2) 0.047 (2 to <16) 0.039 (16+) |
Endpoints | -- | renal (kidney) system, nervous system, developmental | renal (kidney) system | renal (kidney) system | cancer |
CAS number: 93413-69-5 (free base), 93300-78-4 (HCl salt)
Year Adopted: 2023
Volatility: Nonvolatile
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 10 | 10 (2) | 10 (2) | NA |
RfD (mg/kg-day) | -- | 0.0054 | (2) | (2) | -- |
RSC | -- | 0.8 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
Endpoints | -- | developmental, gastrointestinal system, male reproductive system, nervous system (E) | developmental, gastrointestinal system, male reproductive system, nervous system (E) | developmental, gastrointestinal system, male reproductive system, nervous system (E) | -- |
CAS number: 75-01-4
Year Adopted: 2018
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 90 | 10 | 0.2 |
RfD (mg/kg-day) | -- | -- | 0.033 | 0.0030 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 1.4 |
AFlifetime | -- | -- | -- | -- | 1 |
Intake Rate (L/kg-day) | -- | -- | 0.070 | 0.044 | 0.044 |
Endpoints | -- | -- | hepatic (liver) system | hepatic (liver) system | cancer |
CAS number: 1330-20-7
Year Adopted: 2023
Volatility: High
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 700 | 300 | 300 | 300 (3) | NA |
RfD (mg/kg-day) | 1.0 | 0.38 | 0.12 | (3) | -- |
RSC | 0.2 | 0.2 | 0.2 | (3) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.290 | 0.290 | 0.074 | (3) | -- |
Endpoints | nervous system | developmental, nervous system | developmental, renal (kidney) system, nervous system | developmental, renal (kidney) system, nervous system | -- |
The health risk limits established for the specific chemicals in this part supersede the health risk limits for those chemicals in part 4717.7500. For chemicals not included in this part, the health risk limits established in part 4717.7500 remain in place.
Minn. R. agency 144, ch. 4717, HEALTH RISK LIMITS, pt. 4717.7860
Statutory Authority: MS s 103H.201; 144.0751